IQVIA Holdings Inc.
IQV
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $43.4B
$268.95
▲ +1.94%
P/E
33.24
Mkt Cap
$43.4B
52-Wk Range
$154.50–$269.75
52-Week Range
$154.50 - $269.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 42.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive healthcare data platform
- Advanced predictive analytics capabilities
- Global research and consulting network
- Integrated technology and services ecosystem
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Increasing healthcare digitalization
Value
Attractively priced below Life Sciences Tools peer average
Momentum
Hot
+44.9% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying IQV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 28, 2026
Reported EPS of $3.15 vs $3.03 consensus (+4.0% surprise). Revenue of $4.4B vs $4.3B expected (+1.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+4.0%
Revenue trend · last 8Q
—
+2%
+2%
+5%
+5%
+10%
+8%
+9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.9B
$4.0B
$3.8B
$4.0B
$4.1B
$4.4B
$4.2B
$4.4B
Margins · last 8Q
Gross
32.9%
Operating
11.6%
Profit
5.9%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Jul 29, 2026
vs Industry
How IQV stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related